N/A
Manufactured by Insmed Incorporated
37,285 FDA adverse event reports analyzed
Last updated: 2026-04-14
AMIKACIN is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Insmed Incorporated. The most commonly reported adverse reactions for AMIKACIN include OFF LABEL USE, DRUG INEFFECTIVE, COUGH, DYSPNOEA, HOSPITALISATION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for AMIKACIN.
Out of 16,231 classified reports for AMIKACIN:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 37,285 FDA FAERS reports that mention AMIKACIN. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include OFF LABEL USE, DRUG INEFFECTIVE, COUGH, DYSPNOEA, HOSPITALISATION, THERAPY INTERRUPTED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Insmed Incorporated in connection with AMIKACIN. Always verify the specific product and NDC with your pharmacist.